SCREENING ARRAYS TO MONITOR APOPTOSIS GENE EXPRESSION
A quantitative high-throughput gene chip assay, based on nuclease protection, has been developed for drug discovery. The
assay permits the expression levels of numerous genes to be measured
simultaneously in individual samples. We will use this technology to develop an
assay that can measure changes in the expression of pro-apoptotic and
anti-apoptotic genes in cells treated with experimental compounds in a single
well of a 96-well microplate. This assay, performed in 96-well plates, can be
used to screen for novel chemical compounds that induce or inhibit the
expression of apoptotic genes. A drug that can induce the expression of
pro-apoptotic genes and/or decrease expression of anti-apoptotic genes in
cancer cells may prove valuable in the treatment of some types of cancers.
Our patented method applies nuclease protection protocols to gene chips. This
allows DNA array technology to be used in high throughput format with both
sensitivity and reproducibility. Briefly, cells, grown and treated in each well
of a 96-well plate, are lysed in the presence of nuclease protection
oligonucleotides, which hybridize to and protect all targeted mRNA sequences.
After nuclease digestion, oligonucleotides bound stoichiometrically to targeted
sequences are quantified on gene chips. The method is sensitive enough to
measure genes expressed at very low levels -down to one mRNA molecule per cell
in samples of 30,000 cells.
Small Business Information at Submission:
HIGH THROUGHPUT GENOMICS, INC.
HIGH THROUGHPUT GENOMICS, INC. 6296 E GRANT RD TUCSON, AZ 85712
Number of Employees: